Retigabine

Retigabine 구조식 이미지
카스 번호:
150812-12-7
상품명:
Retigabine
동의어(영문):
Ezogabine;Retigabine (Ezogabine); D2312;CS-378;D 23129;Retigabin;Retagabine;RETIGABINE;Retigabine API;Retigabine Base
CBNumber:
CB7506804
분자식:
C16H18FN3O2
포뮬러 무게:
303.33
MOL 파일:
150812-12-7.mol
MSDS 파일:
SDS

Retigabine 속성

끓는 점
430.0±45.0 °C(Predicted)
밀도
1.307±0.06 g/cm3(Predicted)
인화점
2℃
저장 조건
2-8°C
용해도
DMSO: >15mg/mL
물리적 상태
가루
산도 계수 (pKa)
13.12±0.70(Predicted)
색상
흰색에서 밝은 갈색까지
BRN
8072099
안정성
흡습성
CAS 데이터베이스
150812-12-7(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 T,N,Xn,F,Xi
위험 카페고리 넘버 23-25-50/53-36-20/21/22-11
안전지침서 45-60-61-36/37-16-26
유엔번호(UN No.) UN 2811 6.1 / PGIII
WGK 독일 3
유해 물질 데이터 150812-12-7(Hazardous Substances Data)
DEA Controlled Substances CSCN: 2779
CAS SCH: V
NARC: N
그림문자(GHS): GHS hazard pictogramsGHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H410 장기적 영향에 의해 수생생물에 매우 유독함 수생 환경유해성 물질 - 만성 구분 1 경고 GHS hazard pictograms P273, P391, P501
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P270 이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P273 환경으로 배출하지 마시오.
P301+P310 삼켰다면 즉시 의료기관(의사)의 진찰을 받으시오.
NFPA 704
0
2 0

Retigabine C화학적 특성, 용도, 생산

개요

Retigabine was approved in March 2011 by the European Commission for the adjunctive treatment of partial-onset seizures in adults who have epilepsy; in June 2011, the U.S. FDA approved the same drug, known in the United States as ezogabine. Retigabine differs from all currently approved antiepileptic drugs in that it acts as a selective positive allosteric modulator (opener) of KCNQ2-5 potassium channels, which are key regulators of neuronal excitability. The discovery of retigabine was based on modification of an analgesic agent flupirtine that had serendipitously shown potent anticonvulsant activity in animal models of epilepsy. Changing a central 2,3,6-triaminopyridine to a 1,2,4-triaminobenzene decreased analgesic activity while enhancing antiepileptic activity. Retigabine (D-23129) was shown to be a broad spectrum anticonvulsant with oral activity in a variety of animal models. The mechanism of action of retigabine was discovered well after its in vivo activity was recognized. Retigabine is regulated as a Schedule V compound in the United States.

화학적 성질

Purple Solid

용도

Retigabine is a new experimental anticonvulsant drug. It may be used as a reference standard in the determination of retigabine in biological matrices using high-performance liquid chromatography coupled with tandem mass spectrometry with positive ion atmospheric pressure chemical ionization (HPLC-APCI-MS/MS).

정의

ChEBI: A substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults.

일반 설명

Retigabine is an antiepileptic drug, which activates neuronal KCNQ-type K+ channels by inducing a large hyperpolarizing shift of steady-state activation. Retigabine can be prepared by reductive amination of 2-ethoxycarbonylamino-5-(4-fluorobenzylamino)- nitrobenzene with 4-fluorobenzaldehyde, followed by hydrogenation in the presence of Raney nickel.

Mechanism of action

Retigabine has a novel mechanism of action for an antiseizure drug, acting as positive allosteric modulator of the neuronal potassium channels KNCQ (Kv2 to 5).  Under normal physiologic conditions, KNCQ channels help establish the  neuronal resting membrane potential, by providing a continual  hyperpolarizing influence.

Clinical Use

Retigabine is an investigational antiepileptic drug with a novel mechanism of action that involves opening of neuronal voltageactivated K+ channels that serves to stabilize the membrane potential and to control neuronal excitability. Thus, retigabine also may prove to be useful in the treatment of other diseases associated with neuronal hyperexcitability. GSK (GlaxoSmithKline) intends to permanently stop producing this product, trobalt? (retigabine) tablets (50 mg, 100 mg, 200 mg, 300 mg and 400 mg) was no longer be available after June 2017. This is due to the very limited use of the drug, not for reasons of efficacy or safety.

부작용

Dizziness, somnolence, fatigue, confusional state, aphasia, abnormal coordination, tremor, balance disorder, memory impairment, gait disturbance, blurred vision, constipation, anxiety, psychotic disorders, paraesthesia, wt gain, nausea, dyspepsia, urinary retention and hesitation, dysuria; discolouration of ocular tissues (including the retina), skin, lips, and nails; prolongation of QT interval.

Retigabine 준비 용품 및 원자재

원자재

준비 용품


Retigabine 공급 업체

글로벌( 287)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Wuhan Haorong Biotechnology Co.,ltd
+8618565342920
sales@chembj.net China 269 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 7845 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3620 58
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691
yklbiotech@163.com CHINA 296 58
SHANDONG ZHI SHANG CHEMICAL CO.LTD
+86 18953170293
sales@sdzschem.com China 2931 58
Xiamen AmoyChem Co., Ltd
+86-592-6051114 +8618959220845
sales@amoychem.com China 6387 58
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22968 58

Retigabine 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved